BACKGROUND: Accurate, individualized prognostication in patients with oropharyngeal squamous cell carcinoma (OPSCC) is vital for patient counseling and treatment decision making. With the emergence of human papillomavirus (HPV) as an important biomarker in OPSCC, calculators incorporating this variable have been developed. However, it is critical to characterize their accuracy prior to implementation. METHODS: Four OPSCC calculators were identified that integrate HPV into their estimation of 5-year overall survival. Treatment outcomes for 856 patients with OPSCC who were evaluated at a single institution from 2003 through 2016 were analyzed. Predicted survival probabilities were generated for each patient using each calculator. Calculator performance was assessed and compared using Kaplan-Meier plots, receiver operating characteristic curves, concordance statistics, and calibration plots. RESULTS: Correlation between pairs of calculators varied, with coefficients ranging from 0.63 to 0.90. Only 3 of 6 pairs of calculators yielded predictions within 10% of each other for at least 50% of patients. Kaplan-Meier curves of calculator-defined risk groups demonstrated reasonable stratification. Areas under the receiver operating characteristic curve ranged from 0.74 to 0.80, and concordance statistics ranged from 0.71 to 0.78. Each calculator demonstrated superior discriminatory ability compared with clinical staging according to the seventh and eighth editions of the American Joint Committee on Cancer staging manual. Among models, the Denmark calculator was found to be best calibrated to observed outcomes. CONCLUSIONS: Existing calculators exhibited reasonable estimation of survival in patients with OPSCC, but there was considerable variability in predictions for individual patients, which limits the clinical usefulness of these calculators. Given the increasing role of personalized treatment in patients with OPSCC, further work is needed to improve accuracy and precision, possibly through the identification and incorporation of additional biomarkers. Cancer 2019;125:68-78.
INTRODUCTION
Head and neck cancer (HNC) comprises a diverse group of malignancies that arise from multiple subsites and vary with regard to presentation, treatment, and prognosis. 1 Accurate prognostication in patients with HNC is critical to provide effective counseling and individualize optimal treatment. Prognostication in HNC typically is based on tumornode-metastasis (TNM) characteristics as captured in traditional staging systems. 2 As the prognostic importance of additional biomarkers and clinical features has become better appreciated, the need for improved decision-making tools has become apparent. [3] [4] [5] [6] [7] [8] This is particularly salient for patients with oropharyngeal squamous cell carcinoma (OPSCC). Our understanding of the clinical behavior and management of OPSCC has evolved due to the increasing prevalence of human papillomavirus (HPV)-associated disease. 9 Compared with smoking-related and alcohol-related OPSCC, HPV positivity
Cancer January 1, 2019 is associated with an improved prognosis. 10, 11 Due to its distinct presentation and prognosis, a novel staging system for HPV-associated OPSCC has been adopted for the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual. 2, 12, 13 Although the AJCC eighth edition staging system for OSPCC accounts for HPV status, its authors explicitly avoided the incorporation of additional personalized features, favoring instead the more generalizable TNM framework.
14 Despite the prognostic value added by HPV status, subsets of patients continue to demonstrate outcomes discordant with their disease stage. As such, there remains a need for accurate risk stratification that incorporates HPV status as well as other personalized features.
With the goal of providing methods for individualized outcome prediction, numerous multifactorial, patient-specific calculators have been developed for multiple cancer types. 15, 16 To assist with calculator evaluation, the AJCC has published criteria for the endorsement of any probability or risk model. 17 Among the prognostic calculators published in recent years, several have been developed for OPSCC in the HPV era. [18] [19] [20] [21] Although these calculators incorporate additional prognostic factors such as age, smoking history, and TNM classifications in a heterogeneous manner, they all appear to demonstrate impressive accuracy in their respective study cohorts. However, to our knowledge, the generalizability, consistency, and accuracy of these calculators in predicting outcomes for individual patients in diverse populations remain unclear. These uncertainties are critical to address so as to optimally implement these tools into clinical practice. Thus, we sought to characterize and compare the accuracy and precision of existing OPSCC individualized prognostic calculators.
MATERIALS AND METHODS

Patient Selection
Patient data collection, extraction, and analysis were approved by the institutional review board of the University of Michigan. Patient data were extracted from 2 overlapping data sets at the University of Michigan: 1) a prospectively collected epidemiologic database of patients with HNC 6, 7 ; and 2) a database of patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) for OPSCC. 22 Patient data that existed in both data sets were checked individually for agreement, and any conflicting values were resolved by reference to the primary medical record. Patients were diagnosed and treated from 2003 through 2016 as per institutional practices, which were consistent with National Comprehensive Cancer Network guidelines. Because the selected calculators were designed to be used prior to any intervention, clinical information was analyzed, with pathological data substituted only in cases for which clinical information was unavailable.
Prognostic Calculator Selection
Candidate prognostic calculators were identified through a systematic literature search and assessed for eligibility. Inclusion criteria stipulated applicability to OPSCC, provision of 5-year overall survival (OS) prediction, and the inclusion of HPV status as determined by detection of HPV DNA and/or p16.
We identified 4 calculators: 1) one that was developed at the MAASTRO Clinic ("MAASTRO") 20 ; Cancer January 1, 2019
2) one that was based on data from Radiation Therapy Oncology Group ("RTOG") trials 18 ; 3) one that was based on patients treated in eastern Denmark ("Denmark") 19 ; and 4) one that was developed at Erasmus Medical Center ("Erasmus"). 21, 23 24 In our data set, HPV DNA and p16 results were discordant for only 23 patients (2.7%). These patients were differentially classified as either HPV positive or HPV negative depending on the calculator being evaluated. Inputs for each calculator are summarized in Table 2 and Supporting Tables S5-7. Additional details are presented in the Supporting Information.
Statistical Analysis
The predicted 5-year OS was computed for each patient using each calculator. Agreement between predictions was assessed using scatter plots and Spearman correlation coefficients. The ability of each calculator to risk-stratify patients was assessed by dividing subjects into quintiles (5 equally sized groups) based on their predicted risk and using Kaplan-Meier methods to plot their corresponding observed OS. The discriminatory ability of each model was assessed by calculating areas under the receiver operating characteristic (ROC) curve (AUCs) at 5 years 25 and concordance statistics (C-indices). 26 Absolute prediction accuracy was assessed by calibration plots generated using a "moving window" method. For this analysis, patients were divided into multiple overlapping risk groups with calculator-predicted 5-year survival probabilities within a moving window of 0.25. 27 The average predicted 5-year OS for each group then was plotted against the corresponding Kaplan-Meier estimates of 5-year OS. Cancer January 1, 2019
To handle missing covariates, we used a multiple imputation approach based on a multistate cure model (Supporting Fig. 1 ). 28 We used the substantive model compatible-fully conditional specification approach, which involves imputing each covariate with missing values iteratively from a distribution proportional to the likelihood for the multistate cure model and a model for that covariate given the other covariates. 29 Additional details regarding this novel methodology are provided in the Supporting Information. The AJCC 8th N classification for these patients was either N1 or N2.
b
The AJCC 8th group stage was unknown in these patients due to unknown N classification or HPV status.
Cancer January 1, 2019 RESULTS A total of 856 patients were identified for calculator assessment. Patient and disease characteristics are summarized in Table 3 . The median follow-up was 61 months. Approximately 74% of patients and 61% of patients, respectively, had at least 3 years and 5 years of follow-up, or died before 3 years and 5 years. Figure 1 shows the distribution of predictions from the calculators (on the diagonal), scatter plots demonstrating the agreement between pairs of calculators (below the diagonal), and correlation coefficients between predictors (above the diagonal Table 4 lists the percentages of patients for whom each pair of calculators yielded predictions within 10% of each other. For only 3 of the 6 pairings were predicted outcomes within 10% of each other for at least 50% of patients. We next sought to characterize the relative accuracy of each calculator by assessing its ability to stratify patients into risk categories. To do this, we divided patients into equally sized quintile groups based on predicted risk and generated Kaplan-Meier plots of their observed outcomes. Although all calculators yielded the expected distribution of survival outcomes, the MAASTRO and RTOG calculators exhibited relatively poorer differentiation of the 2 lowest risk groups (Fig. 2) .
We next generated ROC curves and calculated AUCs and C-indices (Fig. 3) . There was a range of discriminatory ability among the 4 calculators, with the Denmark model demonstrating the best performance (AUC, 0.80; C-index, 0.78) and the MAASTRO calculator yielding the worst (AUC, 0.74; C-index, 0.71). By comparison, AUCs and C-indices based on clinical stage alone were 0.53 and 0.51, respectively, using the AJCC seventh edition criteria, and were 0.72 and 0.68, respectively, using the AJCC eighth edition criteria (see Supporting Fig. 2 ), indicating inferior discriminatory ability compared with each of the 4 calculators.
We next assessed the absolute predictive accuracy, or calibration, of these calculators by plotting calculator-predicted versus Kaplan-Meier-estimated rates of 5-year OS (Fig. 4) . The Denmark calculator demonstrated the best calibration whereas the MAASTRO calculator underestimated survival and the RTOG and Erasmus calculators overestimated survival for patients at intermediate and low risk, respectively.
DISCUSSION
Using a large patient database, we assessed individualized calculators designed to predict 5-year OS in patients with OPSCC. Although these models demonstrated reasonable risk stratification and discriminatory abilities, we observed suboptimal consistency of predicted outcomes between calculators. In general, the AUCs and C-indices computed in the current analysis were lower than the training values and similar to or higher than the external cohort values previously reported for these calculators, although no external AUC was provided for the Denmark calculator and to our knowledge no training or validation values have been published for the Erasmus one. AUCs and C-indices from each calculator were higher than those obtained from the seventh and eighth editions of the AJCC staging manual. The assessment of absolute predictive accuracy indicated that the Denmark calculator had the best calibration.
Although the OPSCC calculators exhibited reasonable accuracy in the current study, the variability observed among them indicates that the predicted prognosis for a given patient could vary substantially depending on which calculator is used. Communication of accurate information is vital to patient counseling and shared decision making, which has been shown to improve perceived quality of care and patient satisfaction. [30] [31] [32] The results of the current study suggest that although currently available OPSCC calculators may outperform TNM staging, they nevertheless pose the risk of providing inaccurate predictions of prognosis. These results underscore another important issue regarding risk prognostication and patient education. In addition to OS, there are numerous other oncologic and functional outcomes that can be predicted by individualized risk calculators. 15 How to optimally integrate and present different predicted outcomes is unclear at this time, and future work should seek to better define physician and patient preferences and abilities to synthesize this complex information.
In addition to patient education, the accurate prediction of prognosis is becoming increasingly important for determining treatment recommendations and for identifying patients in need of treatment optimization. This is particularly relevant to recent efforts to deintensify treatment in patients with low-risk OPSCC. [33] [34] [35] Although these approaches consistently incorporate HPV Cancer January 1, 2019 status, they heterogeneously account for other prognostic factors. 36 The current study results indicate that individualized risk calculators improve prognostication beyond AJCC staging, even the eighth edition, which incorporates HPV status, and may represent a better method for selecting patients for deintensification. However, the observed variability among calculators suggests that the optimal combination of prognostic variables has not been identified to date. Therefore, further work is needed to improve prognostic calculators with which to guide individualized treatment.
The variability among calculators was likely a function of differences in the variables included, the manner in which the variables were modeled, and the data sources from which the variables were identified. For example, performance of the MAASTRO model may have been impaired by the inclusion of patients treated only with RT or CRT, and not surgery. 20 However, in a separate analysis of the 692 patients treated with RT or CRT in the current study, the MAASTRO calculator again demonstrated inferior performance in comparison with the other models (Supporting Figs. 3-5, Supporting Table S8 ). In addition, the MAASTRO calculator was developed using the smallest training cohort and was the only calculator not to include age, a variable that has been correlated with OS in multiple studies. 37 The RTOG calculator was developed using data from patients treated on RTOG trials 0129 and 0522, and validated in patients treated on the RTOG 9003 trial. 18 Although these trials included patients with HNC of multiple subsites, only patients with OPSCC were used to generate this model. This data source is advantageous in that patient, treatment, and outcome data would be expected to be relatively homogenous, complete, and accurate. However, the inclusion of only those patients treated on clinical trials and the exclusion of patients with an Eastern Cooperative Oncology Group performance status >1 may have limited generalizability. 38, 39 In Figure 1 . Distribution of predicted outcomes (diagonal), scatter plots (below diagonal), and correlation coefficients (above diagonal) for analyzed calculators. Corr indicates correlation; RTOG, Radiation Therapy Oncology Group. Cancer January 1, 2019
addition, in contrast to the other calculators, which more commonly modeled variables as ordinal or continuous, the RTOG model used dichotomization of all variables, which may have impaired performance. The Erasmus model is related to a previously published calculator based on patients treated at Leiden University Medical Center. 40 This "Leiden" calculator performed poorly in an initial analysis (data not shown), most likely because it does not incorporate HPV status. Therefore, we chose to evaluate the Web-based Erasmus calculator, which does include HPV status and is based on a larger, more modern cohort treated at Erasmus Medical Center. 21 This was the only calculator we evaluated for which a full description has not been published to date, although some cohort details have been reported in an analysis of patients with laryngeal cancer. 23 Although the online interface is convenient, the lack of a corresponding publication describing study patients and model performance limits its clinical usefulness. The Erasmus calculator was the only calculator derived from patients with HNC of multiple subsites, with different coefficients being assigned for each subsite. Because the prognostic impact of a given factor could vary among subsites, it is possible that this model could be less accurate than a model developed using only patients with OPSCC or a model that allowed coefficients of other factors to vary by subsite. In addition, this was the only calculator that did not include smoking status, which is an important prognostic factor in both patients with HPV-related and non-HPV-related OPSCC. 7, 10, 41 Of the 4 calculators, the Denmark calculator yielded the highest AUC and C-index, and was the best calibrated. Although to the best of our knowledge there is no consensus, an AUC of ≥0.80 commonly is used to denote "good" discriminatory ability with a high potential for clinical usefulness. 42, 43 With a value of 0.80, the Denmark calculator met this threshold. The Denmark calculator was 1 of 2 models to include treatment modality and did so in a more detailed manner than the Erasmus calculator.
Although these calculators all include HPV status, there are important differences with regard to how this is defined for each. The MAASTRO calculator defines HPV positivity based on the presence of HPV DNA, whereas the RTOG calculator considers only p16. The Denmark calculator considers p16 and HPV DNA separately. The Web site for the Erasmus calculator does not stipulate how HPV status should be determined and, as Cancer January 1, 2019 discussed above, there is no corresponding publication describing how this was defined in model building. It is important to consider how this variability affects the implementation of these calculators. HPV DNA and p16 positivity are correlated but do not completely overlap, 44, 45 and both tests are not performed consistently at all centers. The eighth edition of the AJCC staging manual stipulates that p16 staining be used preferentially to define HPV status. 24 Until it is clear that HPV DNA adds prognostic information beyond p16, it most likely is reasonable to use p16 to define HPV status when using these calculators, with HPV DNA being used as an alternative when p16 is unavailable. If neither HPV DNA nor p16 status are available, caution should be exercised if using these calculators. For staging purposes, in the absence of p16 and HPV status, the eighth edition of the AJCC staging manual recommends staging as if the patient were HPV negative. 24 A similar approach could be taken when using a calculator, although one also could consider calculating an average of predicted outcomes for HPV-positive and HPV-negative iterations or making an educated estimation of the patient's HPV status based on clinical and demographic factors. If any of these is done, the patient should be informed of the limitations of the resulting prediction. This challenge can arise when any prognostic variable is not available, which may limit the usefulness of these models.
The current study is similar to our previous efforts to analyze individual predictors of survival in patients with oral cavity and laryngeal cancer. 27, 46 In the current study, we found OPSCC calculators to yield higher AUCs and C-indices than did oral cavity and larynx models. This is likely due to the availability and incorporation of HPV, a robust biomarker, in the OPSCC calculators. There also were important differences in the data sets used for the larynx and oral cavity compared with OPSCC calculators. Certain of the larynx and oral cavity calculators were developed using the Surveillance, Epidemiology, and End Results database, which, although large, to our knowledge lacks details regarding certain prognostic factors, thereby limiting its usefulness for calculator development. 47 In contrast, the data sets used for the OPSCC calculators were based on institutional and cooperative group databases that contained more detailed information regarding potential prognostic variables. However, all these studies demonstrated substantial variability among calculators that limits their current value. There are limitations to the current study that require consideration. Although the patient data set herein was reasonably comprehensive, there was some degree of missing data (Table 3 ). Because each calculator required different inputs, excluding patients with any missing variable would have reduced the number of evaluable patients substantially. As such, we elected to compensate for the missing covariates via a substantive model compatible-fully conditional specification multiple imputation technique. 29 Although this methodology is rigorous and theoretically justified, it is based on additional statistical models that, although fit to the data, do add additional modeling assumptions. A strength of this approach is that it uses known data to impute related missing covariates. Another limitation to the data set in the current study was that it was comprised of patients who were seen at a single academic institution in the midwestern United States. It is interesting to note that calculators derived from US populations were not found to be better calibrated to the current study patients compared with those developed in Europe. Regardless, it remains unclear how generalizable the results of the current study may be in relation to other institutions. It also is important to note that we evaluated predictions at only one time point: 5 years. Although each calculator also predicts survival at other intervals, 5 years was chosen for this analysis because it is the only time point shared by all 4 models. As a result, we were unable to draw conclusions regarding the performance of these calculators in predicting survival prior to or beyond 5 years.
Although existing OPSCC calculators have demonstrated reasonable predictive accuracy and superior discriminatory ability compared with AJCC TNM staging, a lack of precision limits their usefulness for predicting risk in individual patients. Additional work is needed to improve accuracy and consistency, possibly through the identification of additional biomarkers. 48, 49 With further refinement, multifactorial, patient-specific risk calculators may prove beneficial for individualizing care and improving outcomes in individuals with OPSCC. 
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